



medibio

INVESTOR PRESENTATION

ASX: MEB
OTCPINK: MDBIF

June 2020



LOOKING AT MENTAL HEALTH OBJECTIVELY

A mental health technology company pioneering the use of objective measures to aid in the **early detection** and **screening** of **mental health** conditions.

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks,

The purpose of the presentation is to provide an update of the business of Medibio Limited (**ASX:MEB**) (**OTCPINK: MDBIF**). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

Because actual results could differ materially to assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. Nothing in this presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

WHY INVEST IN MEDIBIO?



EARLY REVENUE

Medibio's corporate mental wellbeing app beginning to gain market traction: early revenue imminent.



INNOVATIVE TECHNOLOGY

The potential to be the world's first objective diagnostic aid of a largely intangible health epidemic: depression



TARGETING A LARGE MARKET

Depression is estimated to cost US economy US\$210 billion a year with the cost in Australia estimated at \$12.6 billion annually



SUPERIOR VALUE PROPOSITION

Objective, non-intrusive software medical device which, upon FDA approval, will enable early identification and will confirm treatment efficacy with data-driven patient management



VALIDATION STUDIES WITH LEADING RESEARCHERS IN THE INDUSTRY

Johns Hopkins University
Emory University
Ottawa University



GLOBAL PARTNERSHIP WITH LEADING RESEARCHERS

Humanitas University, Milan



PATENT PROTECTED TECHNOLOGY

Based on 20 years of research



REGULATORY APPROVALS UNDERWAY

FDA 510K and De Novo
CE Mark

CORPORATE STRUCTURE

ASX: MEB
OTCPINK: MDBIF

Amounts shown in AUD

Market Cap as at 2 June 2020 \$7.0M

Share price as at 2 June 2020 0.7 cents

Issued Shares 1,011M

Listed 12/2021 Options convertible at 3 cents 836M

Net Assets at December 2019 \$13.3M

Cash at March 2020 \$1.0M

TOP 5 SHAREHOLDERS

9.9%	FIDELITY (HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED) Institutional holder
4.2%	CLAUDE SOLITARIO Co-founder and Managing Director
4.0%	HOPERIDGE ENTERPRISES Institutional holder
3.0%	BNP PARIBAS Institutional holder
2.7%	UBS NOMINEES Institutional holder

TOP 20

40%

THE REASON WHY - *PREVALENCE*

350 MILLION

suffer from depression

26%

ADULTS IN US

Leading cause of disability in the US

1 in 13

suffer from anxiety

27%

ADULTS IN EUROPE

7.7M

PTSD sufferers in the United States
alone,
or, **3.5%** of the population

PAIN POINT



Current diagnostic tests rely on **clinical interviews with subjective interpretation**



OUR SOLUTION

Quantitative and objective diagnostic aid based on biomarkers



Concordance rates near **70% for psychiatrists** and **33-50% for primary care physicians**



Repeatable, reliable test
Classification accuracy of 80% in University of Ottawa study.



No objective measure of treatment effectiveness leads to long titration cycles



Provides **objective, data driven indication of treatment efficacy** enabling time to optimal treatment




The standard of care is assessment by a primary care physician > **Higher cost due to misdiagnosis**



Cost-effective, scalable solution that can be administered at the primary care or specialty level > more reliable, repeatable and low cost

REVENUE OPPORTUNITIES




REGULATED PATH

DEPRESSIVE BURDEN TRIAL

Aims to confirm Medibio's unique Software Medical Device (SoMD)'s capacity to **objectively** identify depressive burden in patients with primary (e.g. hypersomnia, insomnia) and secondary (e.g. obstructive sleep apnea) sleep disorders.

FDA De Novo Clearance

Class I or II Device



NON - REGULATED PATH



ilumen

An **early intervention** solution, offering objective data to manage and improve **employee mental health**. **ilumen** provides actionable and valuable insights.



We ***close the loop*** for employers to measure and manage their people's mental wellbeing

HOW DOES ILUMEN™ WORK?

ilumen™ measures mental well-being in three easy steps

- 1** Employees download the ilumen™ app and complete a series of questions to assess their mental wellbeing. Participants may repeat the assessments every two weeks to monitor their progress.
- 2** Connect a wearable device (optional). This allows biometric data such as sleep and activity metrics.
- 3** Results allow employees to monitor and manage a full spectrum of factors influencing mental state over time and take actionable steps to improve them.



ASSESS

Download the App and take the assessment



TRACK

Connect biometric data



MANAGE

Monitor, adjust, and improve over time

"I have started seeing a psychologist and I showed her my results yesterday. I'm going to see my GP to seek some kind of treatment further to seeing a psychologist and practising techniques." – ilumen user

CLOSING THE LOOP

With ilumen's Corporate Dashboards employers are now able to measure the success of the mental health strategies they implement. Employers will now KNOW if a mental health program has been effective and whether it has been successful in improving the mental well-being of its workforce. Medibio, through ilumen™, offers the "missing link" to employers to optimise and achieve a fully effective workplace.



FOR EMPLOYERS

Provides employers with a real-time, de-identified, aggregated dashboard of their workforce's results to better support and manage the mental well-being of its workforce and measure the impact of their programs.



FOR EMPLOYEES

Provides employees an early screening tool for symptoms of stress and a 'well-being snapshot' they can use to make improvements over time.

ILUMEN™ PROGRESS TO DATE

Whilst participation by employees in ilumen™ is voluntary, participation rates have been as high as 75%. The engagements below represent the commercial validity and acceptance of ilumen™ in 2019.

In September 2019 Medibio signed a commercial agreement with a division of Anglo American Plc. Participants were located in Singapore, United Kingdom, Australia, Chile, Brazil and South Africa.

In October 2019 Medibio secured an annual license agreement for ilumen™ with PriceWaterhouseCoopers Australia (approx 9000 employees).

During 2019 Medibio completed four ilumen™ pilot programs with Compass Group Plc, the largest food service organisation in the world, with 650,000 employees globally. The programs were conducted within the Business & Industry Division, Offshore & Remote Division and Defence Division in the United Kingdom; and the Remote & Offshore Division in Australia.

In February 2020, Medibio signed an annual licence agreement with Stantec, a global engineering, design and related professional services firm.



OUR MILESTONES 2020 - 2021 CALENDAR YEARS

MILESTONE

TIMING

First Annual License Contract for ilumen Secured with PwC

Dec Qtr, 2019

FDA 510K application for sleep staging software: MEBsleep

Jun Qtr, 2020

Secure Australian Master Service Agreement for ilumen with key client/partner

Jun Qtr, 2020

Secure Australian Reseller Agreement for ilumen with key client/partner

Sep Qtr, 2020

FDA determination for sleep staging software: MEBsleep

Sep Qtr, 2020

Secure Global Master Service Agreement for ilumen with key client/partner

Sep Qtr, 2020

CE Mark application and determination for sleep staging software, MEBsleep

Sep Qtr, 2020

Agreement with FDA on patient numbers for Depressive Burden confirmatory study

Dec Qtr, 2020

Complete development of mental health app for Consumer Market (new product)

Mar Qtr, 2021

FDA submission - Depressive Burden Software Medical Device
WORLD'S FIRST OBJECTIVE DIAGNOSTIC AID FOR DEPRESSION

Jun Qtr, 2021

BOARD OF DIRECTORS



CLAUDE SOLITARIO
Managing Director



PETER CARLISLE
Non - Executive Director
Managing Director, Olympics &
Action Sports, Octagon Worldwide



MELANIE LEYDIN
Director & Joint Company
Secretary
CA, FGIA



MATTHEW WATKINS
Joint Company Secretary
B. Bus. (Acc) Swinburne, CA

GROWTH & ADVOCACY ADVISORY BOARD



PETER CARLISLE
Managing Director, Olympics &
Action Sports, Octagon Worldwide



MICHAEL PHELPS
Mental Health Advocate



PATRICK KENNEDY
Former US Congressman
Founder, Kennedy Forum



Pioneering the use of objective measures with artificial Intelligence and neural network methodology to aid in the early detection and screening of mental health conditions



medibio

CLAUDE SOLITARIO
Managing Director

Melbourne
Level 4, 100 Albert Road
South Melbourne VIC
3205

United States HQ
8696 Eagle Creek Circle
Savage, MN 55378